Literature DB >> 29588318

Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.

Takemasa Tsuji1,2, Akira Yoneda1, Junko Matsuzaki1,2, Anthony Miliotto1, Courtney Ryan1, Richard C Koya1,2, Kunle Odunsi3,2,4.   

Abstract

T cells genetically engineered with tumor antigen-specific T-cell receptor (TCR) genes have demonstrated therapeutic potential in patients with solid tumors. In order to achieve broader application, an efficient method to identify TCR genes for an array of tumor antigens and HLA restriction elements is required. Here, we have developed a method to construct a TCR-expression library from specimens, including frozen tumor biopsies, that contain antigen-specific T cells. TCR-expressing cassettes were constructed and cloned in a retroviral plasmid vector within 24 hours by unbiased PCR amplification of TCR α and β chain variable regions assembled with TCR constant regions. The method was validated by constructing TCR-expressing vectors from tumor antigen-specific T-cell clones and functionally assessing TCR gene-transduced T cells. We applied this method to frozen ovarian tumor specimens that were infiltrated by tumor antigen-specific T cells. The tumor-derived TCR libraries were expressed in peripheral T cells from healthy volunteers and screened for tumor antigen-specific TCR pairs with the use of an MHC/peptide tetramer reagent. Tumor antigen-specific TCR-expressing transgenes were recovered from isolated tetramer-positive T cells. Peripheral T cells that were engineered with library-derived TCR gene showed potent therapeutic antitumor effect in a tumor xenograft model. Our method can efficiently and rapidly provide tumor-specific TCR-expressing viral vectors for the manufacture of therapeutic and personalized antitumor T-cell products. Cancer Immunol Res; 6(5); 594-604. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29588318      PMCID: PMC5932240          DOI: 10.1158/2326-6066.CIR-17-0434

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  44 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Pairing of T-cell receptor chains via emulsion PCR.

Authors:  Maria A Turchaninova; Olga V Britanova; Dmitriy A Bolotin; Mikhail Shugay; Ekaterina V Putintseva; Dmitriy B Staroverov; George Sharonov; Dmitriy Shcherbo; Ivan V Zvyagin; Ilgar Z Mamedov; Carsten Linnemann; Ton N Schumacher; Dmitriy M Chudakov
Journal:  Eur J Immunol       Date:  2013-06-26       Impact factor: 5.532

Review 3.  Selection strategies for anticancer antibody discovery: searching off the beaten path.

Authors:  David Sánchez-Martín; Morten Dræby Sørensen; Simon Lykkemark; Laura Sanz; Peter Kristensen; Erkki Ruoslahti; Luis Álvarez-Vallina
Journal:  Trends Biotechnol       Date:  2015-03-26       Impact factor: 19.536

Review 4.  Adoptive Cellular Therapy (ACT) for Cancer Treatment.

Authors:  Fan Yang; Hao Jin; Jian Wang; Qian Sun; Cihui Yan; Feng Wei; Xiubao Ren
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Authors:  Thinle Chodon; Begoña Comin-Anduix; Bartosz Chmielowski; Richard C Koya; Zhongqi Wu; Martin Auerbach; Charles Ng; Earl Avramis; Elizabeth Seja; Arturo Villanueva; Tara A McCannel; Akira Ishiyama; Johannes Czernin; Caius G Radu; Xiaoyan Wang; David W Gjertson; Alistair J Cochran; Kenneth Cornetta; Deborah J L Wong; Paula Kaplan-Lefko; Omid Hamid; Wolfram Samlowski; Peter A Cohen; Gregory A Daniels; Bijay Mukherji; Lili Yang; Jerome A Zack; Donald B Kohn; James R Heath; John A Glaspy; Owen N Witte; David Baltimore; James S Economou; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

6.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

7.  Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.

Authors:  Virginie Vignard; Brigitte Lemercier; Annick Lim; Marie-Christine Pandolfino; Yannick Guilloux; Amir Khammari; Catherine Rabu; Klara Echasserieau; François Lang; Marie-Lise Gougeon; Brigitte Dreno; Francine Jotereau; Nathalie Labarriere
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

8.  Expression of two T cell receptor alpha chains: dual receptor T cells.

Authors:  E Padovan; G Casorati; P Dellabona; S Meyer; M Brockhaus; A Lanzavecchia
Journal:  Science       Date:  1993-10-15       Impact factor: 47.728

9.  Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Authors:  Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Shinya Tanaka; Kenji Chamoto; Tingxi Guo; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2015-02-20       Impact factor: 5.422

10.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

View more
  5 in total

Review 1.  Viral Vectors in Gene Therapy.

Authors:  Kenneth Lundstrom
Journal:  Diseases       Date:  2018-05-21

2.  Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

Authors:  Song Liu; Junko Matsuzaki; Lei Wei; Takemasa Tsuji; Sebastiano Battaglia; Qiang Hu; Eduardo Cortes; Laiping Wong; Li Yan; Mark Long; Anthony Miliotto; Nicholas W Bateman; Shashikant B Lele; Thinle Chodon; Richard C Koya; Song Yao; Qianqian Zhu; Thomas P Conrads; Jianmin Wang; George L Maxwell; Amit A Lugade; Kunle Odunsi
Journal:  J Immunother Cancer       Date:  2019-06-20       Impact factor: 12.469

3.  WHSC1/NSD2 regulates immune infiltration in prostate cancer.

Authors:  Muzamil Y Want; Takemasa Tsuji; Prashant K Singh; James L Thorne; Junko Matsuzaki; Ellen Karasik; Bryan Gillard; Eduardo Cortes Gomez; Richard C Koya; Amit Lugade; Kunle Odunsi; Sebastiano Battaglia
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

4.  Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.

Authors:  Junko Matsuzaki; Shashikant Lele; Kunle Odunsi; Takemasa Tsuji
Journal:  Oncoimmunology       Date:  2022-01-05       Impact factor: 7.723

5.  Massively parallel interrogation and mining of natively paired human TCRαβ repertoires.

Authors:  Matthew J Spindler; Ayla L Nelson; Ellen K Wagner; Natasha Oppermans; John S Bridgeman; James M Heather; Adam S Adler; Michael A Asensio; Robert C Edgar; Yoong Wearn Lim; Everett H Meyer; Robert E Hawkins; Mark Cobbold; David S Johnson
Journal:  Nat Biotechnol       Date:  2020-03-16       Impact factor: 54.908

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.